A recent Palliative Care digest,
as sent to subscribers

Study Type: Cross-sectional analysis of a nationwide bereaved family survey (Japanese palliative care units); univariable analyses only.

Key Question: How do bereaved family members experience a patient's desire to hasten death (DHD), and what factors are associated with their distress?

Key Findings:

• DHD was reported in 24% of 475 respondents (114/475); 35% of these involved an explicit request. Reasons were physical symptoms (80%) and existential distress (65%).
• 75.8% (72/95) were distressed or very distressed; ~50% felt helpless or unsure how to respond, and ~25% reported unmet emotional support or guidance needs.
• ~70% found DHD understandable and supported suffering relief including sedation; ~30% wished it could be fulfilled. Distress was associated with spousal relationship, existential-rooted DHD, coping difficulty and emotional overwhelm.

Clinical Relevance: Distress persisted despite cognitive understanding of DHD, supporting proactive family support and guidance when DHD arises, including in UK specialist palliative care.

Limitations: Retrospective bereaved-report design with 52.5% response rate and univariable-only analysis limits causal inference, and findings may not generalise beyond the Japanese context.

Study Type: Feasibility and implementation study (LLM validation against expert-adjudicated reference standard, followed by pilot and enterprise-wide deployment). Single health system; appears US-based.

Key Question: Can an LLM embedded in the EHR reliably detect goals-of-care (GOC) documentation in free-text notes and surface it to clinicians in real time?

Key Findings:

• GPT-4o performance against the reference standard: specificity 0.95, recall 0.74, precision 0.78. Expert audit of AI-flagged notes (n=325) showed 86% agreement. No significant performance differences by race, sex, or age.
• Enterprise deployment identified ~37,000 patients with GOC documentation in ~2 months.
• Patients with flagged documentation had higher ICU stay ≥5 days (30.2% vs 8.2%), in-hospital mortality (14.9% vs 0.6%), hospice discharge (10.5% vs 0.4%) and code status changes (29.3% vs 9.9%).

Clinical Relevance: Findings suggest the feasibility of surfacing buried GOC conversations, relevant to NHS ReSPECT and advance care planning visibility, though UK EHR fragmentation and information governance would limit direct transferability.

Limitations: Recall of 0.74 means roughly a quarter of GOC documentation was missed, and the abstract provides no evidence that detection improved goal-concordant care, so the stated conclusion is not directly supported by the outcomes reported (the outcome comparisons are descriptive and unadjusted).

Study Type: Qualitative interview study (grounded theory principles); 64 parents of 44 children and 34 physicians, Netherlands.

Key Question: How do parents and physicians interpret suffering in children aged 1–12 with life-threatening conditions, and how do adaptation and opportunities for ordinary childhood shape those judgements?

Key Findings:

• Suffering was conceptualised across three overlapping domains: physical, psychological and existential.
• Judgements depended on impact on enjoyment, relationships, participation, agency and continuity of ordinary childhood, not symptoms or functional limitation alone.
• Apparent adaptation lowered perceived suffering; limited communication or consciousness made suffering harder to judge.

Clinical Relevance: Supports a structured, multi-perspective approach to assessing suffering in children with life-limiting conditions, relevant to UK paediatric palliative care and shared decision-making with families.

Limitations: Single-country sample (interviews 2016–2018) limits transferability to UK settings, and the proposed reflective framework is not yet validated.

Study Type: Secondary analysis of existing data (observational, descriptive); 12 US hospices, n = 1338.

Key Question: What proportion of hospice patients with heart failure (HF) and dementia stop HF-related medications at admission, and does this differ by whether HF is the primary or secondary hospice diagnosis?

Key Findings:

• Pre-hospice use was highest for beta-blockers (44.0%), loop diuretics (32.4%) and RAAS inhibitors (17.7%).
• Among documented users, discontinuation at admission was 91.2–100% across classes: beta-blockers 97.5%, loop diuretics 97.0%, RAAS inhibitors 94.1%.
• Discontinuation did not differ by HF diagnostic primacy (primary n = 210; secondary n = 1128).

Clinical Relevance: Near-universal deprescribing of HF medications, including loop diuretics, at hospice admission may reflect practice that UK clinicians should compare with their own, particularly given the risk of symptomatic congestion.

Limitations: Prescribing rationale and post-discontinuation symptom outcomes were not assessed, so appropriateness and harms cannot be judged (US setting limits generalisability to NHS hospice care).

Study Type: Cross-sectional descriptive study (single centre, n=100)

Key Question: What is the prevalence of wish to hasten death (WTHD) in advanced cancer patients under palliative care in Argentina, and which factors predict it?

Key Findings:

• WTHD was identified in 35% of patients (AFEDD severity 2–7, median 5); most were at the lower end of the continuum without active planning.
• Higher WTHD was associated with greater symptom burden (median ESAS-r 41 vs 31; p<0.001) and demoralization (62.9% vs 23.1%; p<0.001).
• Demoralization was the only independent predictor on multivariate analysis (OR 6.56; 95% CI 2.47–18.53).

Clinical Relevance: Supports routine screening for demoralization (e.g. DS-II) when WTHD is expressed, which may prompt psychosocial and existential interventions rather than a purely symptom-focused response.

Limitations: Cross-sectional, single-centre design with a small sample precludes causal inference and limits generalisability (including to UK populations); the abstract also contains apparent data-presentation errors in the severity-group definitions.

Study Type: Retrospective cohort study (single-cohort analysis, n=120).

Key Question: Are longitudinal changes in inflammatory (C-reactive protein-to-albumin ratio, ΔCAR) and nutritional (body weight) status associated with survival in patients with advanced pancreatic cancer at the third-line/best supportive care stage?

Key Findings:

• High ΔCAR and weight loss were each associated with shorter overall survival, and both were independent prognostic factors alongside ECOG PS.
• Median survival was 1.38 months with both high ΔCAR and weight loss versus 4.67 months with neither.
• ΔCAR and weight loss were associated with appetite loss and worsening PS. Hazard ratios and confidence intervals are not reported in the abstract.

Clinical Relevance: Serial CRP/albumin and weight, both routinely available in NHS settings, may help identify patients with APC entering a rapid decline phase, supporting timely prognostic discussion and advance care planning.

Limitations: Retrospective, single-cohort design with no external validation and unclear ΔCAR cut-offs or timing; the observed associations may reflect disease progression rather than independent prognostic value.

Study Type: Quasi-experimental pre-post study (single-programme, n=83), analysed with Kaplan-Meier and Cox regression.

Key Question: Does substituting hydromorphone for morphine in Colorado's Medical Aid in Dying (MAiD) protocol alter time to sleep or time to death?

Key Findings:

• Median time to death was similar: 55 min (hydromorphone) vs 65.5 min (morphine); p=0.29.
• Median time to sleep was shorter with hydromorphone: 3 vs 5.5 min (p=0.0007).
• Age-adjusted hazard ratio for faster sleep was 2.08 (95% CI 1.29–3.36).

Clinical Relevance: Assisted dying is not currently lawful in England and Wales, so there is no direct practice application. However, it is relevant to UK clinicians following the ongoing legislative debate and to those counselling patients on the pharmacology of opioid-related end-of-life events.

Limitations: Pre-post design from a single programme, with a small sample and only age adjusted for, leaves substantial scope for confounding (e.g. changes in co-prescribed agents, patient characteristics, or timing assessment).

Study Type: Expert practice-guidance article (narrative, "top ten tips" format); not original research or a systematic review.

Key Question: What is the current evidence for, and how should palliative care clinicians apply and interpret, urine drug testing (UDT) in patients receiving opioid therapy?

Key Findings:

• The abstract reports no quantitative data, effect sizes, or primary findings; it does not state the methodology used to select evidence or reach consensus.
• The authors state that UDT is commonly used in palliative care to mitigate nonmedical opioid use (NMOU), but that its role is not well defined.
• The article offers ten tips covering the evidence base, appropriate use, result interpretation, and how to act on results. The specific recommendations are not given in the abstract.

Clinical Relevance: Given the lack of clear UDT guidance in UK palliative care, this may offer practical interpretive support, though it appears to be US-framed and may not reflect NHS testing availability or local policy.

Limitations: Expert opinion without a stated systematic or consensus methodology, so recommendations cannot be graded for strength of evidence from the abstract alone.